Startup Showcase: Mogrify – Pioneering Next-Generation Cell Therapies

1 min read

Mogrify is a UK-based biopharmaceutical startup that is on a mission to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies. With a proprietary direct cellular reprogramming platform, Mogrify is paving the way for a new era in regenerative medicine. Let’s take a closer look at this game-changing startup.

Proprietary Direct Cellular Reprogramming Platform

Mogrify’s direct cellular reprogramming platform is the cornerstone of its technology. It allows for the systematic enhancement of stem cell-derived reprogramming and the direct conversion of mature cell types into other mature cell types without going through a pluripotent stem cell or progenitor cell state. This revolutionary platform has been protected by foundational patent applications and additional patent applications covering improvements and extensions to the core platform and specific cell conversions.

Scalable Source of Functional Cell Types

Mogrify is applying its proprietary platform to generate a scalable source of functional cell types required to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies. The potential applications of this technology are numerous, including immuno-oncology, ophthalmology, and other disease areas with high unmet clinical needs.

Business Model of Internal Cell Therapy Development

Mogrify’s business model is based on internal cell therapy development, co-development partnerships, and the exploration and generation of novel cell-based and in vivo reprogramming therapies for broad therapeutic application. With a regenerative medicine market estimated to be worth $39 billion USD by 2023, Mogrify is uniquely positioned to address this growing market.

Read more from UKT News:  Startup Showcase: Moorgate Benchmarks - Bridging the Gap in Index Creation

Commercial Potential

Mogrify has won multiple awards and has already achieved significant milestones. The company has raised $16 million in series A funding and has secured multiple partnerships to develop its platform for specific cell therapies. Its potential for a wide range of applications makes it an attractive partner for pharmaceutical companies, biotech firms and other stakeholders in the life sciences industry.

Conclusion

Mogrify’s innovative technology and business model have the potential to revolutionize the world of regenerative medicine. With a mission to transform the development of cell therapies and pioneer a new class of in vivo reprogramming therapies, Mogrify is poised to make a significant impact on the healthcare industry. Keep an eye on this startup as it has the potential to change the game for good.

Website: https://mogrify.co.uk/

Twitter: https://twitter.com/mogrify_uk

LinkedIn: https://www.linkedin.com/company/mogrify-developing-next-generation-cell-therapies/


Want to supercharge your brand’s visibility within the UK tech industry? Reach startup founders, investors, and C-level executives with sponsored articles on UKT.news. Connect with us and discover how our advertising solutions can propel your brand to new heights. Explore our Sponsored Articles & Partnerships Program here.

Read more from UKT News:  Is This Gateshead Startup Revolutionising Digital Marketing and Lead Generation?

UKT News

UKT.news is a media platform owned by Unstructured Media, providing the latest news and insights on UK technology and startup scenes. The website offers readers with daily updates on the latest industry developments, as well as featuring exciting startups and advertising opportunities.

Leave a Reply

Your email address will not be published.